← Research library

Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1

Patent disclosure · 2008

What the patent describes
Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
Reported evidence
The patent describes 123 patients with blast-related mixed hearing injury. Its tables report complete restoration in 22.3%, improvement in 34.7% and no effect in 43% following combined treatment. Tinnitus improvement is also reported.

Reported patent results

Reported findings

Hearing improved in some patients, while 43% had no reported treatment effect.

Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.

Population or model Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.

Results · Description: 123-patient observations and Tables 2–3; tinnitus narrative.
MeasureResultComparison, timing and statistics
Hearing outcome22.3% complete restoration, 34.7% improvement, 43% unchangedReported proportions; no modern randomized comparison established · After the treatment course
Hearing thresholdsAverage reductions reported in the 15–30 dB rangeWithin-cohort change across speech/high frequencies · p<0.05 reported
Tinnitus49 patients reported complete disappearance; 9 less intensity; 5 unchanged63/123 had tinnitus initially; percentages in the source use the whole cohort denominator
Comparison with prior methodsComplete restoration 22.3% versus 7.3% and 9.8%; no effect 43% versus 67% and 64%Comparator cohort sizes and concurrent comparability are not established

Combined procedures, heterogeneous injuries, unclear comparator allocation and inconsistent percentage totals prevent a reliable Dalargin-alone effect estimate.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Use. A Dalargin method relating to blast-associated hearing injury; disease-specific patent claims do not establish routine clinical benefit.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2323019C1 ↗ · 2008-04-27
Earliest priority / filing
2006-11-23 / 2006-11-23
Original applicant / assignee
Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
39453032 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method for treating patients for posttraumatic sensorineural deafness in acute stage caused by mine explosion injury

Inventors: Эльвира Татаркановна Гаппоева (RU); Эльвира Татаркановна Гаппоева.

RU2323019C1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent case material does not establish randomized allocation, blinding or Dalargin monotherapy efficacy.
  • One narrative passage reverses the restoration/improvement percentages; the summary follows the results tables.
  • Mixed middle- and inner-ear injuries and associated procedures limit attribution.

Source details

Selected source text and metadata checked; full risk-of-bias review pending.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1 Russian patent RU2323019C1

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards